$25B+ Cell Therapy Market 2030
CAR-T Cancer Immunotherapy
6 FDA-Approved CAR-Ts
iPSC Stem Cell Platform
Allogeneic Off-the-Shelf
TCR-T Next-Gen Therapies
MSC Regenerative Medicine
GMP Manufacturing
$25B+ Cell Therapy Market 2030
CAR-T Cancer Immunotherapy
6 FDA-Approved CAR-Ts
iPSC Stem Cell Platform
Allogeneic Off-the-Shelf
TCR-T Next-Gen Therapies
MSC Regenerative Medicine
GMP Manufacturing
Living Medicine Platform

Cells as
Medicine.

Advanced cell therapy development platform for CAR-T, stem cells, and regenerative medicine. Engineer living drugs that cure.

CAR TARGET TARGET TARGET TARGET CELL THERAPY
$25B+
Market by 2030
6
FDA-Approved CAR-Ts
90%
ALL Remission Rate
1000+
Clinical Trials

Cell Therapy Platform

Engineering living drugs for cancer, autoimmune, and regenerative medicine.

??

CAR-T Cells

Chimeric antigen receptor T-cells targeting CD19, BCMA, and novel antigens for cancer.

??

TCR-T Cells

T-cell receptor engineered cells for solid tumors and intracellular antigens.

??

iPSC Platform

Induced pluripotent stem cell-derived therapies for scalable allogeneic products.

??

MSC Therapy

Mesenchymal stem cells for regenerative medicine and immunomodulation.

???

NK Cells

Natural killer cell therapies for off-the-shelf cancer immunotherapy.

??

GMP Manufacturing

Automated, closed-system cell manufacturing for clinical and commercial scale.

Industry Leaders

Organizations advancing cell therapy technology.

Bristol Myers SquibbCAR-T
Breyanzi, Abecma - approved CAR-T therapies
NovartisPioneer
Kymriah - first FDA-approved CAR-T
Legend BiotechBCMA
Carvykti for multiple myeloma
Fate TherapeuticsiPSC
iPSC-derived NK and T-cell therapies
AllogeneAllogeneic
Off-the-shelf allogeneic CAR-T
CRISPR TherapeuticsGene Edit
Gene-edited cell therapies

Own Cell Therapy

CellTherapy.app - the premium domain for living medicine and cellular therapeutics.

Inquire About This Domain

Own Celltherapy

This premium domain is available for acquisition. Perfect for companies, startups, or investors in this space.

Submit your inquiry below and we'll respond within 24 hours.